India Approves First Dengue Vaccine for Broad Age Group
The Drug Controller General of India has granted market authorization for the QDENGA vaccine, a two-dose shot designed to combat all four dengue serotypes. The vaccine, developed by Takeda and manufactured in partnership with Biological E. Limited, is approved for individuals aged 4 to 60 without the need for prior screening.
In a significant development for public health, the Drug Controller General of India (DCGI) has officially approved QDENGA (TAK-003), the country’s first licensed vaccine against dengue fever. This milestone, reported by Firstpost, marks a shift in the national strategy to manage a disease that contributes to a substantial portion of the global health burden annually.
)
The vaccine, developed by Takeda Biopharmaceuticals, is a live-attenuated tetravalent shot designed to provide protection against all four dengue virus serotypes. A critical advantage of this approval is the vaccine's versatility; it is cleared for use in individuals aged 4 to 60 years and, unlike previous iterations of dengue vaccines, does not require pre-vaccination blood testing to confirm prior exposure to the virus. The administration protocol involves two subcutaneous doses, with the second dose scheduled three months after the first.
This approval follows a rigorous clinical evaluation process. Globally, Takeda’s development program encompassed 19 trials involving over 28,000 participants. Domestically, the vaccine’s safety and efficacy were validated through the Phase III DEN-302 trial, which demonstrated a robust immune response across various age demographics. To ensure domestic availability, Takeda has entered into a manufacturing partnership with the Hyderabad-based firm Biological E. Limited. This collaboration aims to produce up to 50 million doses annually, a capacity intended to bolster future public immunization initiatives.
While QDENGA has already received regulatory clearance in over 40 jurisdictions, including the European Union and Brazil, India continues to pursue indigenous solutions as well. The Indian Council of Medical Research (ICMR) is currently collaborating with Panacea Biotec on a separate tetravalent vaccine candidate, DengiAll, which is presently in Phase III clinical trials.
For decades, India’s approach to dengue has been primarily reactive, focusing on mosquito control measures and supportive clinical care. The introduction of a vaccine provides a new preventive layer to this framework. As the country grapples with the seasonal rise of mosquito-borne illnesses, the integration of this vaccine into the public health landscape is expected to be a key focus for health authorities in the coming months.